What I saw in the trial data is that participants in Phase 2 received the drug at no cost and had close medical monitoring throughout
CagriSema is under FDA review with a decision expected by late 2026, and the RENEW program will give us a fuller picture of what cagrilintide can do as a standalone treatment
GLP-1s are not recommended for people with medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease
Sugary Beverages Sodas, fruit juices, sweetened coffee drinks, and energy drinks add liquid calories without satiety
*Medications require consultation and prescription by clinician through Noom platform
Health Canada approval typically follows FDA approval by 6 to 18 months, placing realistic Canadian availability between late 2027 and mid 2028